MDWD
MediWound Ltd.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
4.94
P/S
10.77
EV/EBITDA
-12.81
DCF Value
$-28.58
FCF Yield
-11.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
19.2%
Operating Margin
-149.1%
Net Margin
-140.8%
ROE
-65.8%
ROA
-27.7%
ROIC
-41.3%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $1.9M | $-7.2M | $-0.56 |
| FY 2025 | $17.0M | $-23.9M | $-2.10 |
| Q3 2025 | $5.4M | $-2.7M | $-0.24 |
| Q2 2025 | $5.7M | $-13.3M | $-1.23 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
IL
Exchange
NASDAQ
Beta
0.15
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.